Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Ho hlakisoa ha letlalo la Atopic Dermatitis ka kalafo e ncha

ngotsoeng ke mohlophisi

Ho feta karolo ea 50 lekholong ea bakuli ba nang le "atopic dermatitis" e leka-lekaneng ho isa ho e matla (AD) ba bile le phokotso ea karolo ea 75 lekholong ea ho teba ha mafu (EASI-75*) libeke tse 16 ha ba amohela lebrikizumab monotherapy lenaneong la Advocate, Almirall SA (BME: ALM). ) e phatlalalitsoe kajeno Sebokeng sa Selemo le Selemo sa American Academy of Dermatology (AAD). Lebrikizumab, e leng IL-13 inhibitor ea lipatlisiso, le eona e lebisitse ntlafatsong e nang le morero ho itch le liphetho tse ling tsa bohlokoa tse tlalehiloeng ke bakuli ha li bapisoa le placebo.              

"Matšoao a atopic dermatitis a kang ho hlohlona, ​​letlalo le omeletseng, bohloko bo tebileng le ho ruruha ho nka moroalo o boima bophelong ba bakuli hammoho le bophelo bo botle ba bona. Bakuli ba batla meriana e fanang ka mekhoa ea phekolo e sebetsang hantle le e mamelloang hantle e ka sebetsanang le matšoao ao le ho ntlafatsa boleng ba bophelo ba bona. Lebrikizumab ke kalafo e ncha e nang le thibelo e khethehileng ea IL-13, mokena-lipakeng o bohareng oa pathogenic ho AD. Bokhoni bo hlokometsoeng ba lebrikizumab liphuputsong tsena bo tiisa bokhoni ba phekolo ena e ncha, e ka bang tlatsetso e amohelehang ho atopic dermatitis armamentarium, "ho boletse Prof. Dr. med. Diamant Thaçi, Mookameli Setsing se Felletseng sa Meriana ea ho Ruruha Univesithing ea Lübeck Jeremane, le mofuputsi ea ka sehloohong oa teko ea ADvocate 2.

Lebrikizumab ke monoclonal antibody (mAb) e tlamang protheine ea interleukin 13 (IL-13) e nang le kamano e phahameng ho thibela ka ho khetheha ho thehoa ha IL-13Rα1 / IL-4Rα (Mofuta oa 2 receptor) e thibelang pontšo e tlaase ka IL-13. tsela. 1-5 IL-13 e bapala karolo e ka sehloohong ho ho ruruha ha Mofuta oa 2. Ka AD, IL-6 e fana ka matšoao le matšoao a kenyeletsang ho se sebetse ha mokoallo oa letlalo, ho hlohlona, ​​tšoaetso le libaka tse thata, tse teteaneng tsa letlalo.13

Ho 'Muelli oa 1, karolo ea 43 lekholong ea bakuli ba fumanang lebrikizumab e fihletse letlalo le hlakileng kapa le batlang le hlakile (IGA) libeke tse 16 ha li bapisoa le liperesente tse 13 tsa bakuli ba nkang placebo. Har'a ba fumanang lebrikizumab, karolo ea 59 lekholong e fumane karabo ea EASI-75, ha e bapisoa le karolo ea 16 lekholong e nang le placebo.

Ho 'Muelli oa 2, karolo ea 33 lekholong ea bakuli ba nkang lebrikizumab ba fihletse letlalo le hlakileng kapa le batlang le hlakile (IGA) libeke tse 16, ha li bapisoa le liperesente tse 11 tsa bakuli ba placebo. Har'a ba fumanang lebrikizumab, karolo ea 51 lekholong e fumane karabo ea EASI-75, ha e bapisoa le karolo ea 18 lekholong e nkang placebo.

Nakong ea libeke tse 'nè, bakuli ba fumanang lebrikizumab ba ile ba fumana ntlafatso e kholo ea lipalo-palo tabeng ea ho hloekisoa ha letlalo le ho hlohlona, ​​hammoho le ntlafatso ea ho kena-kenana le ho hlohlona ha boroko, le boleng ba bophelo, joalokaha ho lekantsoe ke lintlha tsa bohlokoa tsa bobeli.

Boemo ba polokeho ea nako ea libeke tse 16 bo ne bo lumellana le lithuto tsa pele tsa lebrikizumab ho AD. Bakuli ba nkang lebrikizumab, ha ba bapisoa le placebo, ba tlalehile makhetlo a fokolang a liketsahalo tse mpe ho ADvocate 1 (lebrikizumab: 45%, placebo: 52%) le Advocate 2 (lebrikizumab: 53%, placebo: 66%). Liketsahalo tse mpe ka ho fetisisa ho pholletsa le lithuto tse peli li ne li le bonolo kapa li itekanetse ka matla le tse se nang letho 'me ha lia ka tsa lebisa ho khaotsoe ke phekolo. Liketsahalo tse mpe tse atileng haholo ho Advocate 1 le 2 bakeng sa ba lebrikizumab e ne e le conjunctivitis (7% le 8%, ka ho latellana), sefuba se tloaelehileng (nasopharyngitis) (4% le 5%, ka ho latellana) le hlooho (3% le 5%, ka ho latellana). ).

"Lintlha tse ncha tse ntle tse tsoang lithutong tsa Mokhahlelo oa 3 oa monotherapy Advocate 1 le Advocate 2 tse hlahisitsoeng Sebokeng sa Selemo sa Selemo sa American Academy of Dermatology li bontša hore lebrikizumab e na le monyetla oa ho ba kalafo e ka sehloohong bakeng sa moloko o mocha oa biologics. Bakuli ba hloka mekhoa e mecha ea phekolo e fanang ka katleho e phahameng le mamello e ntle. Ketsahalo ena ea bohlokoa e boetse e re susumetsa hore re tsoele pele ho tsepamisa boiteko ba rona ho e 'ngoe ea lihlahisoa tsa rona tsa morao-rao le ho ntšetsa pele boitlamo ba rona ba ho ntlafatsa boleng ba bophelo ba bakuli ka mekhoa e mecha ea phekolo," ho boletse Karl Ziegelbauer, Ph.D., Ofisiri e ka Sehloohong ea Saense ea Almirall SA.

Liphetho tse felletseng tsa libeke tse 52 ho tsoa ho Advocate 1 le 2, hammoho le data ea libeke tse 16 ho tsoa ho ADhere, thuto ea Phase 3 AD ea lebrikizumab e nang le li-topical steroids, e tla senoloa likhoeling tse tlang. Almirall le Eli Lilly and Company ba rera ho tlisa lifaele ho balaoli ba tsamaiso lefats'eng ka bophara bofelong ba 2022 kamora ho phethoa ha lithuto tsa Akhente.

"Re lebelletse ho arolelana liphetho tsa nako e telele ho tsoa ho Advocate 1 le 2 selemong sena, tseo re lumelang hore li tla totobatsa hape hore lebrikizumab e ka fana ka phomolo e hlokahalang haholo bakeng sa batho ba loanang le lefu lena le sa foleng, hangata, le bophelo bohle," ho boletse Lotus. Mallbris, MD, Ph.D., motlatsi oa mopresidente oa nts'etsopele ea lefats'e ea immunology le litaba tsa bongaka Lilly.

Almirall e fane ka tumello ea ho hlahisa le ho rekisa lebrikizumab bakeng sa kalafo ea matšoao a letlalo, ho kenyeletsoa AD, Europe. Lilly o na le litokelo tse khethehileng bakeng sa nts'etsopele le khoebo ea lebrikizumab United States le lefats'eng lohle ka ntle ho Europe.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...